Key points are not available for this paper at this time.
The RS may be an effective risk stratifier for the outcomes of FGC patients and may be used to select patients who can benefit from NIPS therapy.
Share your take
Add a clinician perspective alongside expert commentary.
Wang et al. (Fri,) studied this question.